Completed PHASE3 INTERVENTIONAL 1-arm NCT00209391

A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide

A Multicentre, Phase 3, Open-Label, Controlled Study Evaluating the Efficacy and Safety of 0.1 mmol/kg OMNISCAN (Gadodiamide Injection) in Magnetic Resonance Angiography (MRA) of the Renal Arteries

Sponsor: GE Healthcare

Conditions Renal Artery Stenosis

Interventions Gadodiamide Injection

Updated 6 times since 2017 Last updated: Apr 24, 2019 Started: Sep 30, 2003 Primary completion: Aug 1, 2005 Completion: Aug 1, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Renal Artery Stenosis and is currently completed. GE Healthcare leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
May 2019 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — May 2019 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Sep 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GE Healthcare

Data source: GE Healthcare

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Ismaning, Germany